Targeted News Service

FDA Proposes New Endpoints to Accelerate Multiple Myeloma Drug Approvals
January 21, 2026

WASHINGTON, Jan. 21 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration introduced a draft guidance that recommends using minimal residual disease and complete response as primary endpoints in clinical trials for multiple myeloma treatments. This move is intended to speed up the delivery of drug and biological products to patients by utilizing more sensitive markers of treatment success.

Multiple myeloma is a malignancy of the plasma cells and re . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form